Share on StockTwits
 

Shares of MedAssets (NASDAQ:MDAS) have received a consensus recommendation of “Buy” from the sixteen brokerages that are presently covering the stock, ARN reports. Eight equities research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $25.68.

Several analysts have recently commented on the stock. Analysts at RBC Capital initiated coverage on shares of MedAssets in a research note on Thursday. They set a “sector perform” rating and a $21.00 price target on the stock. Separately, analysts at Zacks upgraded shares of MedAssets from an “underperform” rating to a “neutral” rating in a research note on Monday, January 6th. They now have a $20.50 price target on the stock. Finally, analysts at JPMorgan Chase & Co. initiated coverage on shares of MedAssets in a research note on Monday, December 9th. They set a “neutral” rating and a $23.00 price target on the stock.

Shares of MedAssets (NASDAQ:MDAS) traded down 3.03% during mid-day trading on Friday, hitting $20.82. The stock had a trading volume of 213,856 shares. MedAssets has a 52 week low of $16.31 and a 52 week high of $26.58. The stock’s 50-day moving average is $20.94 and its 200-day moving average is $22.54. The company has a market cap of $1.288 billion and a price-to-earnings ratio of 255.60.

MedAssets, Inc (NASDAQ:MDAS) provides technology-enabled products and services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.